Cytora is on a mission to make it standard practice for people to be treated with off-the-shelf (allogeneic) Stem Cell medicines, derived from the readily accessible oral mucosa termed human oral mucosa stem cells - hOMSC, for some of the toughest diseases within this decade, including Parkinson’s, Multiple System Atrophy (MSA), Alzheimer’s Dementia, and non-healing diabetic wounds (IDFU).
Cytora is a portfolio company of Galil Ofek Innovations, a peripheral technology incubator focused primarily on biomedical technologies such as medical devices.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
BiologicalsCells
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
/PRNewswire/ -- Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSCs), reported today...